title: Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation.
abstract: New-onset diabetes after transplantation (NODAT) is a growing concern in transplantation. All modifiable risk factors are not yet identified. We assessed the relationship between baseline clinical and biochemical parameters and NODAT. Eight-hundred and fifty-seven in-Caucasian renal transplant recipients were included. Charts were individually reviewed. The follow-up was 5.3 years (ranges: 0.25-20.8; 5613 patient-years). The incidence of NODAT was 15.0%, 18.4% and 22.0% at 10, 15 and 20 years following transplantation. Age, body mass index (BMI), glucose (all P < 0.0001) and triglycerides [hazard ratio (HR) per 1 mmol/l: 1.44 [1.17-1.77], P = 0.0006] were potent risk factors whereas steroid withdrawal (HR: 0.69 [0.47-1.01], P = 0.0601) reduced the risk. As compared to cyclosporine, sirolimus (HR: 3.26 [1.63-6.49], P = 0.0008) and tacrolimus (HR: 3.04 [2.02-4.59], P < 0.0001) were risk factors for NODAT. The risk of NODAT was comparable for sirolimus (HR: 2.35 [1.06-5.19], P = 0.0350) and tacrolimus (HR: 2.34 [1.46-3.75], P = 0.0004) after adjustments on age, BMI, glucose and steroid withdrawal; however, unlike sirolimus, tacrolimus remained significant after adjustment on triglycerides. The risk of NODAT appeared similar, but its pathophysiology seemed different in sirolimus- and tacrolimus-treated patients; this observation needs confirmation. However, main independent risk factors were age, BMI, initial glucose and triglycerides.
authors.affiliation: Service de Néphrologie-Immunologie Clinique, Hôpital Bretonneau, CHRU Tours, Tours, France.
authors.forename: Mélanie
authors.initials: M
authors.lastname: Roland
authors.forename: Philippe
authors.initials: P
authors.lastname: Gatault
authors.forename: Claire
authors.initials: C
authors.lastname: Doute
authors.forename: Matthias
authors.initials: M
authors.lastname: Büchler
authors.forename: Azmi
authors.initials: A
authors.lastname: Al-Najjar
authors.forename: Christelle
authors.initials: C
authors.lastname: Barbet
authors.forename: Valérie
authors.initials: V
authors.lastname: Chatelet
authors.forename: Jean-Frédéric
authors.initials: JF
authors.lastname: Marlière
authors.forename: Hubert
authors.initials: H
authors.lastname: Nivet
authors.forename: Yvon
authors.initials: Y
authors.lastname: Lebranchu
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Halimi
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D016572:Cyclosporine / Q000009:adverse effects; D003920:Diabetes Mellitus / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012307:Risk Factors; D020123:Sirolimus / Q000009:adverse effects; D016559:Tacrolimus / Q000009:adverse effects; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D007166:Immunosuppressive Agents; D014280:Triglycerides; D016572:Cyclosporine; D020123:Sirolimus; D016559:Tacrolimus